Spravato treatment for Palm Beach Gardens — REMS-certified, insurance-covered TRD care.

For Palm Beach Gardens residents managing treatment-resistant depression, RECO Integrated Psychiatry's Delray Beach office is a 35-minute drive down I-95 — and one of the few REMS-certified Spravato sites in South Florida delivering the full eight-session induction protocol under direct psychiatrist supervision. In-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS, with concurrent oral antidepressant management handled by the treating psychiatrist rather than punted to an outside prescriber. PHQ-9 and GAD-7 tracked at every visit; no waitlist for consultation.

Palm Beach Gardens sits 25 miles north of RECO Integrated Psychiatry’s Delray Beach office, roughly 35 minutes down I-95 when traffic cooperates. For residents of PGA National, Mirasol, BallenIsles, Frenchman’s Reserve, or Old Palm managing treatment-resistant depression, the drive south places specialist interventional psychiatry — including Spravato (esketamine) treatment under full REMS certification — inside a manageable weekly commute. Northern Palm Beach County has plenty of talk therapists and generalist psychiatrists; what it lacks is the concentration of on-site esketamine dosing, rTMS, and complex medication management that a specialty outpatient clinic delivers under one roof.

Spravato and the REMS protocol — what treatment actually looks like

Spravato is esketamine, the S-enantiomer of ketamine, delivered as a nasal spray under the FDA’s Risk Evaluation and Mitigation Strategy. Because dissociation, sedation, and transient blood-pressure elevation are expected effects, the drug can only be administered at a certified treatment center where the client stays for two hours of post-dose monitoring. RECO is REMS-registered; the enrollment paperwork, specialty pharmacy coordination, and per-session documentation are handled by the office rather than by the client.

The session itself is uncomplicated. A nurse verifies vitals and confirms the client has not eaten within two hours. The client self-administers the spray under supervision — two or three devices depending on the 56 mg or 84 mg dose. From there it is two hours of monitoring: blood pressure at 40 minutes when cardiovascular and dissociative effects peak, the Clinician-Administered Dissociative States Scale (CADSS) to quantify dissociation, and periodic sedation checks. Clients cannot drive afterward; a ride home is required every visit, and rideshare qualifies.

Most clients describe the first hour as floaty or dreamlike, with dissociation resolving well before the two-hour window closes. Nausea is the most common side effect; ondansetron is available on-site. Persistent blood-pressure elevation or unusual sedation extends monitoring but rarely aborts a session.

The induction and maintenance schedule

For treatment-resistant major depressive disorder, induction is twice weekly for four weeks — eight sessions — at 56 mg for session one and 84 mg from session two forward, with a dose reduction back to 56 mg permitted if tolerability is the limiting factor. Weeks five through eight step down to once weekly. From week nine, maintenance runs every one to two weeks, adjusted to PHQ-9 trajectory and functional response.

The MDD-with-acute-suicidal-ideation indication uses a compressed twice-weekly-for-four-weeks protocol, at which point the psychiatrist and client decide whether to transition to a TRD-style maintenance schedule or step down to oral therapy alone. Clients typically feel some initial mood shift within the first week or two; sustained response — a durable PHQ-9 drop holding across weekly visits — usually consolidates by session six or seven.

Discontinuation is done on a taper, not abruptly. The evidence base for tapering is thinner than the evidence base for induction, so decisions to space beyond every two weeks lean on the client’s response curve, prior antidepressant history, and life-stage transitions.

Spravato with an oral antidepressant, not instead of one

The FDA approval is specifically for esketamine plus an oral antidepressant — monotherapy is off-label and not what the pivotal trials studied. Clients arriving on a partial-response SSRI or SNRI (sertraline, escitalopram, venlafaxine, duloxetine) typically continue that agent through induction; the assumption is that Spravato augments the existing antidepressant rather than replaces it.

Clients who have failed multiple antidepressant trials often start or switch an oral agent at the same time as beginning Spravato. That may mean initiating a new SSRI, adding an atypical antipsychotic such as aripiprazole or quetiapine for augmentation, or in selected cases layering lithium. RECO’s psychiatrists manage the concurrent regimen as part of the treatment plan — Spravato is not a standalone product delivered in isolation from the rest of the medication picture.

Clients who have historically responded to bupropion or mirtazapine usually stay on those agents. Benzodiazepines, when present, are typically held the morning of a session to avoid stacking sedation.

Spravato versus IV ketamine — how the decision gets made

Both Spravato and IV racemic ketamine target the NMDA receptor, and both produce rapid antidepressant effects that oral agents cannot. The practical differences drive the choice. Spravato is FDA-approved for TRD and MDD-with-suicidality; commercial insurers — Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, BCBS — cover it once two documented antidepressant failures at adequate dose and duration are on file. IV ketamine is off-label for depression, almost always cash-pay, and priced per infusion.

Dosing differs. Spravato is fixed at 56 or 84 mg per session. IV ketamine allows weight-based titration — typically 0.5 mg/kg over 40 minutes — adjusted to prior response. Time in office is comparable: two hours for Spravato, roughly two hours end-to-end for an IV infusion including pre- and post-monitoring.

Clients who need insurance coverage, prefer the nasal route, or want a fixed protocol lean Spravato. Clients with atypical response profiles or who have plateaued on esketamine and need titratable dosing may be candidates for an IV ketamine consultation. RECO’s psychiatrists lay out both paths at intake without pushing one over the other.

What to expect on the first visit from Palm Beach Gardens

The initial appointment is a 60- to 75-minute psychiatric evaluation, not a same-day dosing session. The psychiatrist reviews the depression history, prior medication trials (agent, dose, duration, response, side effects — this documentation drives TRD eligibility and insurance authorization), suicidality and safety history, medical comorbidities, and the current medication regimen. Baseline PHQ-9 and GAD-7 are administered and repeated at each subsequent visit to track trajectory objectively.

If Spravato is the correct fit, the office submits prior authorization while REMS enrollment is completed in parallel. Most authorizations return within five to ten business days; first dosing is typically scheduled within two weeks of the consult. Clients traveling from PGA National or Mirasol should book mid-morning first appointments to skirt southbound I-95 rush hour.

Insurance and admissions from Palm Beach Gardens

RECO Integrated Psychiatry is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS. Spravato-specific coverage requires documented failure of at least two oral antidepressants at adequate dose and duration; intake captures this history in the format insurers expect. Copays and coinsurance vary by plan; admissions runs a benefits check before the first dosing session so the client knows per-session out-of-pocket before beginning induction.

Admissions from Palm Beach Gardens can be initiated by phone or through the website. Records from prior psychiatrists — medication lists, response history, hospitalization notes when applicable — accelerate prior authorization and are worth requesting before the first appointment.

Serving residents of: BallenIsles, Frenchman's Reserve, Mirasol, Old Palm, PGA National.